^
    4d
    Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma. (PubMed, Clin Cancer Res)
    The greatest benefits of encorafenib plus binimetinib were observed in patients with evidence of high TMB and/or tumor immune infiltration, suggesting potential immune contributions to efficacy, which were not observed with vemurafenib. BRAF V600 detectability in ctDNA appears to have utility as a marker of prognosis and response in this population.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • IFNG (Interferon, gamma)
    |
    PD-L1 expression • BRAF V600E • TMB-H • BRAF V600 • BRAF V600K
    |
    Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
    6d
    NCI-2013-02103: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (clinicaltrials.gov)
    P1/2, N=75, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    THXID® BRAF Kit • cobas® 4800 BRAF V600 Mutation Test
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263) • omipalisib (GSK2126458)
    7d
    RAMP 203: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (clinicaltrials.gov)
    P1/2, N=153, Active, not recruiting, Verastem, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Avmapki (avutometinib) • Fakzynja (defactinib)
    10d
    Newly Synthesized Telmisartan-Amino Acid Conjugates Exhibit Enhanced Cytotoxic Effects in Malignant Melanoma Cells. (PubMed, Molecules)
    These three compounds were also tested on the vemurafenib-resistant (A375R) and normal (HaCaT and MRC-5) cell lines, and compound 8 showed better cytotoxicity (IC50 = 8.84 ± 1.24 µM) and selectivity (>3.50) when compared to telmisartan (IC50 = 29.23 ± 3.88, selectivity > 2.40). All three compounds induced cell cycle arrest and disrupted mitochondrial morphology and membrane potential. These findings highlight their potential as non-antihypertensive telmisartan derivatives for melanoma therapy.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib)
    11d
    Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy. (PubMed, Cancer Med)
    Data from this study provides provocative evidence that, while BRAF+/-MEK inhibitor therapy produces an increase in overall and clonal T cell infiltrates, there is limited evidence for generation of new or persistent tumor immunity. Thus, BRAFi/MEKi therapy may enable tumor-reactive T cells to infiltrate tumors but tumor control does not appear to depend on priming new immune responses.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib)
    13d
    Pediatric Long-Term Follow-up and Rollover Study (clinicaltrials.gov)
    P4, N=165, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting | Trial completion date: Jul 2026 --> Nov 2026
    Enrollment open • Trial completion date
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    14d
    Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (clinicaltrials.gov)
    P1, N=31, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    everolimus • Avmapki (avutometinib) • Fakzynja (defactinib)
    15d
    Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    15d
    From a Long-Standing Yellowish Plaque to a Diagnosis of a Rare Disorder: A Case of Erdheim-Chester Disease Treated With Vemurafenib. (PubMed, Am J Med Genet A)
    In conclusion, our case highlights that the primary diagnostic clue for ECD may be a single yellowish plaque, which requires further investigation in relation to other systemic symptoms. Vemurafenib treatment may lead to regression of systemic symptoms and cutaneous yellowish plaques associated with ECD carrying a BRAF mutation.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule) • F13A1 (Coagulation Factor XIII A Chain)
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib)
    18d
    A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with BRAF V600E mutation. (PubMed, Front Med (Lausanne))
    The postoperative pathology review revealed a pathological complete response (pCR). This case illustrates that BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor therapy may represent a viable option for neoadjuvant therapy in locally advanced BRAF V600E mutant NSCLC.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    BRAF V600E • BRAF V600 • ALK mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    22d
    Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study. (PubMed, Neurooncol Pract)
    No treatment-related deaths were reported. In pediatric patients with relapsed orrefractory BRAF V600-mutated HGG, dabrafenib exhibited sustained objective tumor responses and a manageable safety profile.
    P1/2 data • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    Tafinlar (dabrafenib)
    30d
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | N=156 --> 267 | Trial completion date: Sep 2028 --> Apr 2030 | Trial primary completion date: Mar 2027 --> Oct 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride